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Abstract 
Glioblastomas (GBM) are lethal brain tumors where poor outcome is attributed to cellular 
heterogeneity, therapeutic resistance, and a highly infiltrative nature. These characteristics 
are preferentially linked to GBM cancer stem cells (GSCs), but how GSCs maintain their 
stemness is incompletely understood and the subject of intense investigation. Here, we 
identify a novel signaling loop that induces and maintains GSCs consisting of an atypical 
metalloproteinase, a disintegrin and metalloproteinase domain-like protein decysin 1 
(ADAMDEC1), secreted by GSCs. ADAMDEC1 rapidly solubilizes fibroblast growth factor-2 
(FGF2) to stimulate FGF receptor 1 (FGFR1) expressed on GSCs. FGFR1 signaling induces 
upregulation of Zinc-finger E-box-binding homeobox 1 (ZEB1) via ERK1/2 that regulates 
ADAMDEC1 expression through miR-203, creating a positive feedback loop. Genetic or 
pharmacological targeting of components of this axis attenuates self-renewal and tumor 
growth. These findings reveal a new signaling axis for GSC maintenance and highlight 
ADAMDEC1 and FGFR1 as potential therapeutic targets in GBM.  
 
Statement of Significance 
Cancer stem cells (CSC) drive tumor growth in many cancers including glioblastoma. We 
identified a novel sheddase, a disintegrin and metalloproteinase domain-like protein decysin 
1, that initiates a fibroblast growth factor autocrine loop to promote stemness in CSCs. This 
loop can be targeted to reduce glioblastoma growth. 
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Introduction 
Glioblastoma (GBM) is a uniformly fatal disease with a median survival of 
approximately 20 months after diagnosis (1-3). GBM represents a prototypical example of a 
highly heterogeneous tumor with multiple distinct, identifiable molecular subclasses within a 
single tumor (4,5). Frequent tumor recurrence and poor outcome are thought to be a 
consequence of resident GBM cancer stem cell (GSC) populations resistant to current 
therapies (6-8). Thus, GSCs are a candidate population for tumor recurrence (9-12). A 
recent study demonstrates that GBM contains GSC populations that produced non-stem 
tumor cell (NSTC) progenies, with only GSCs capable of propagating tumor formation (13). 
How GSCs are maintained across the changing tumor microenvironment within hypoxic, 
vascular, or invasive niches (14) remains unclear. 
Tumor progression is frequently linked to the secretion of metalloproteinases that 
enable tissue invasion and intravasation by cancer cells via extracellular matrix (ECM) 
degradation. This also causes a release of trophic factors to stimulate tumor growth, 
dispersal, and modulation of inflammatory responses. Members of the A Disintegrin and 
Metalloproteinase (ADAM) family of zinc-dependent proteinases contribute to GBM 
therapeutic resistance and invasiveness (15,16), as well as to the regulation of GSCs (17-
19). ADAMDEC1 is a soluble member of this family that is novel in mammals. It has 
restricted hydrolytic capacity due to a substitution of an active site residue (20) and 
selectively solubilizes growth factors from immobile precursor forms (21). Whether 
ADAMDEC1 solubilizes additional ligands, and whether this contributes to GBM growth and 
progression, has yet to be determined. 
Trophic factors from the tumor microenvironment are essential to GBM growth and 
GSC maintenance. Fibroblast growth factor 2 (FGF2) is crucial in normal neural 
development and stem cell function, and a known oncogenic factor in GBM (22). FGF2 
promotes glioma growth and vascularization (23) and GSC self-renewal (24). Nevertheless, 
how FGF2 specifically contributes to GSC functions is incompletely understood. 
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We now find ADAMDEC1 initiates FGF2 signaling through FGFR1 and ERK1/2 that 
then mediates GSC self-renewal and maintenance through induction of the stem cell 
transcription factor, ZEB1. ZEB1 additionally induces expression of ADAMDEC1 through 
miR-203, completing a positive feedback loop and contributing to GSC maintenance in the 
tumor microenvironment. Importantly, we show that pharmacological intervention at the level 
of FGF2 can disrupt this loop and may constitute a translational therapeutic strategy. 
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Results 
Given the role for some of the ADAM family of metalloproteinases in GBM growth 
and progression (17,19), we assessed the entire family for members that are elevated in 
GBM and may contribute to tumor growth. We interrogated the bioinformatics database 
GlioVis (25) for mRNA expression levels of ADAM family members across multiple GBM 
datasets (Fig. 1A). When normalized to brain expression levels, ADAMDEC1 emerged 
among the top proteases upregulated in GBM. Further investigation of these candidates 
using TCGA and LeeY data sets revealed that ADAMDEC1 was the only protease where 
increased expression associated with poorer prognosis of GBM patients (Fig. 1B, S1A,B). 
TCGA data also demonstrate that ADAMDEC1 mRNA levels increase with glioma grade 
(Fig. 1C). We performed immunohistochemistry on patient specimens to test whether this 
extends to the protein level and found elevated ADAMDEC1 in GBM (Fig. 1D). Fluorescence 
immunostaining in patient-derived xenograft models revealed that ADAMDEC1 was 
expressed by tumor cells, and not host microglia (Fig. 1E). 
We evaluated a role for ADAMDEC1 in maintaining stemness by first enriching GSC 
and NSTC populations by CD133 expression. Physical separation of the cell types showed 
increased cellular protein expression of ADAMDEC1 in CD133+ cells compared to their 
CD133- counterparts across multiple patient-derived cell lines (Fig. 2A). Furthermore, testing 
conditioned media from GSC and NSTC cultures revealed that GSCs exclusively secrete 
ADAMDEC1. To evaluate a functional role for ADAMDEC1 in GSC maintenance, we 
knocked down ADAMDEC1 expression using lentiviral delivery of short hairpin RNA 
(shRNA) constructs. We found ADAMDEC1 knockdown reduced expression of the stem-cell 
associated transcription factor SOX2 and increased expression of astrocytic differentiation 
marker GFAP (Fig. 2B). ADAMDEC1 knockdown also decreased in vitro sphere formation 
(Fig. 2C) and proliferation (Fig. 2D) of primary patient-derived GBM cells compared to non-
targeted controls. To further scrutinize the relevance of ADAMDEC1, we orthotopically 
implanted ADAMDEC1 knockdown cells into immunocompromised mice, and observed a 
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significant increase in survival of tumor-bearing mice compared to controls (Fig. 2E, S2A). 
These data demonstrate ADAMDEC1 is a key regulator of GSCs.  
 As ADAMDEC1 is a sheddase capable of processing cytokines, we next determined 
whether ADAMDEC1 promoted GBM growth and progression via cytokine release. We 
treated GSCs and matching NSTCs with recombinant (r) ADAMDEC1 for 48 hours, after 
which conditioned media was collected and multiple cytokines were evaluated using anti-
cytokine bead based flow cytometry (Fig. 2F). This experiment showed a dose-dependent 
increase of soluble FGF2 in the culture media with increasing amounts of rADAMDEC1. Pre-
treatment of cells with proteolytic enzymes blocked this effect, indicating that rADAMDEC1 
released FGF2 from the ECM, rather than inducing FGF2 secretion from cells (Fig. S2B). In 
contrast, GRO alpha release was unaffected by rADAMDEC1. We evaluated FGF2 release 
over time using ELISA to find that GSC, but not NSTC, cultures released FGF2 within 
minutes following treatment with rADAMDEC1 (Fig. 2G). Finally, ADAMDEC1 knockdown 
resulted in reduced activation of FGFR signaling, as demonstrated by western blotting using 
a pan-phospho-FGFR antibody, whereas rADAMDEC1 treatment increased FGFR 
phosphorylation (Fig. 2H). 
We next sought to define how FGF2 acts on GSCs by testing whether FGF2 
correlated with the GSC-associated transcription factors ZEB1, SOX2, or OLIG2 (26). Using 
TCGA gene expression data, we found each of these transcription factors correlated with 
FGF2 (Fig. 3A, S3). To validate these correlations, we used patient-derived GBM cells that 
had been cultured in EGF only, and treated these cultures with recombinant FGF2. We 
found that rFGF2 dose-dependently induced expression of ZEB1, SOX2 and OLIG2 (Fig. 
3B). In functional assays, rFGF2-treatment increased sphere formation (Fig. 3C). 
Conversely, a small-molecule inhibitor identified in a screen to block the interaction between 
FGF2 and FGF receptors (2-Naphthalenesulfonic acid, NSC 65575) (27) reduced 
clonogenicity (Fig. 3D) and sphere formation (Fig. S4A), but not viability (Fig. S4B,C), of 
patient-derived GBM cells. Together, these results implicate FGF2 in GSC activation. 
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FGF2 can bind to FGFR1-4, therefore we used a bioinformatic approach to 
determine whether any FGFRs show association with GBM patient outcome. We performed 
hierarchical cluster analysis of TCGA data using FGF2, FGFR1-4, ZEB1, SOX2 and OLIG2 
as determinants. This revealed the existence of three principal clusters (Fig. 3E), with cluster 
1 comprising of ~30% of samples and showing association of FGF2, FGFR1-3 and stem cell 
transcription factors (ZEB1, OLIG2, and SOX2). Cluster 2 was the smallest and showed low 
expression of FGF2, FGFR1-3 and stem cell transcription factors. Conversely, this was the 
only cluster where FGFR4 was present. Cluster 3 constitutes most (>50%) of the samples, 
and shows high expression of ZEB1, SOX2, and OLIG2, but not of FGF2 or its receptors. 
Gene set enrichment analysis revealed an overlap of cluster 1 with signatures of the 
classical and mesenchymal molecular subclasses (4), while cluster 2 showed positive 
correlation with mesenchymal and negative correlation with all other signatures, and cluster 
3 was enriched for neural and proneural subclass signatures (Fig. S5).  
Because data in the TCGA repository may be affected by the presence of non-tumor 
cells in patient specimens, we validated our cluster analysis in the HGCC dataset, which is 
derived from patient cell lines (28). Consistently, we found all three clusters represented. In 
this dataset, FGFR1 was strongest associated with cluster 1, which was also most enriched 
for the mesenchymal subclass (Fig. 3E). This demonstrates an association of FGF2 and 
stemness-associated transcription factors in a significant fraction of GBM specimens and 
that considerable heterogeneity exists among these samples. 
We used Kaplan-Meier analysis of the TCGA Glioblastoma Multiforme (provisional) 
dataset to further investigate which FGFR may be most relevant for patient outcome. This 
analysis confirmed that high expression of FGFR1 is associated with poor outcome, while for 
FGFR2 the relationship was inverse of this with augmented FGFR2 expression correlating to 
a better prognosis (Fig. 3F). No significant correlation was apparent for FGFR3 and patient 
survival. Of note, combinatorial analysis for FGFR1 and ADAMDEC1 showed a strong 
association with survival. 
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We next determined the FGFR expression in patient-derived GBM cells and found 
that FGFR1-3 were expressed, but that FGFR4 was consistently absent (Fig. 4A), as 
suggested by our cluster analyses (Fig. 3E). Using flow cytometry to quantify FGFR1-3 
expression on GBM cells (Fig. 4B, S6A,B), we found FGFR1 present on a small subset of 
cells (1-5%), consistent with a stem cell population. By contrast, FGFR2 was expressed on a 
large fraction (30-50%) of cells. FGFR3 expression showed large variance, ranging from 5-
25%. To test the functional relationship of different FGFR subtypes with GSCs, we 
performed lentiviral shRNA-mediated knockdown of FGFR1-3 in patient-derived GBM cells 
(Fig. 4C, S6C). We found that only FGFR1 loss resulted in a decrease of sphere forming 
capacity (Fig. 4D), which was accompanied by a decrease in ZEB1, SOX2, and OLIG2 
expression (Fig 4E) and a decrease in proliferation (Fig. S6D). Loss of FGFR1 or ZEB1, but 
not of FGFR2 or FGFR3, abolished the FGF2-mediated increase in self-renewal (Fig. 
S6E,F). Importantly, FGFR1 knockdown increased survival of tumor-bearing mice after 
orthotopic transplantation (Fig. 4F), and reduced tumorigenesis upon limiting-dilution 
orthotopic transplantation (Fig. 4G), revealing an approximate 6-fold enrichment of GSCs in 
control vs. shFGFR1 cells. 
To further substantiate this pivotal role of FGFR1 in GSCs, we performed rescue 
experiments. Targeted expression of full-length FGFR1 increased expression of ZEB1, 
SOX2 and OLIG2 in control cells, and restored ZEB1, SOX2 and OLIG2 expression in 
FGFR1 knockdown cells (Fig. 4H). Concomitantly, over-expression of FGFR1 increased 
sphere formation in control and FGFR1 knockdown cells (Fig. 4I). By contrast, ZEB1 
knockdown negated the effects of FGFR1 over-expression on levels of SOX2 and OLIG2 
expression, as well as on sphere formation, indicating that ZEB1 is downstream of FGFR1, 
and upstream of SOX2 and OLIG2. 
As FGFR1 is functionally relevant for stem cell maintenance in GBM, we 
hypothesized that this receptor may identify a GSC population. To test this hypothesis, we 
first quantified FGFR1 expression under culture conditions conducive to GSC maintenance 
(sphere cultures supplemented with mitogens) or differentiation (adherent cultures with 
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growth factor withdrawal, supplemented with serum or BMP4). We found that FGFR1 
expression is high in GSC cultures, whereas FGFR1 levels decrease under differentiation 
conditions (Fig. 5A, S7A). The expression of the stem cell transcription factors ZEB1, SOX2 
and OLIG2 followed the same pattern. By contrast, FGFR2 and FGFR3 expression 
increased in differentiation conditions (Fig. 5A). To test whether FGFR1 may be a marker of 
GSCs, we isolated FGFR1-expressing cells via flow cytometry (Fig. 5B). Using an 
independent FGFR1-antibody, we confirmed increased FGFR1 expression in the FGFR1+ 
fraction. Likewise, expression of ZEB1, SOX2 and OLIG2 were enriched in the FGFR1+ 
fraction (Fig. 5B). Next, we tested FGFR1+ cells in functional assays for stemness 
immediately after FACS. We found that FGFR1+ cells showed greater clonogenicity than 
FGFR1- cells in a limiting-dilution experiment (Fig. 5C). Finally, we used limiting dilution 
orthotopic xenografts to determine the stem cell frequency of FGFR1+ and FGFR1- cells 
(Fig. 5D). Extreme limiting dilution analysis (29) demonstrated an approximate 5-fold 
enrichment of GSCs in FGFR1+ cells, consistent with our results in limiting-dilution of 
FGFR1-knockdown cells (Fig. 4G). Together, these data strongly support that (i) FGFR1 
transduces FGF2 signal to induce GSC self-renewal, (ii) ZEB1, SOX2 and OLIG2 are 
downstream targets of FGF2/FGFR1 signaling, and (iii) FGFR1 is a surface marker of 
GSCs.  
Our results indicate that GSCs secrete ADAMDEC1, causing release of FGF2 that 
induces GSC maintenance via FGFR1 signaling to ZEB1. We next sought to address how 
the expression of ADAMDEC1 in GSCs might be regulated. Speculating that ZEB1 may 
induce ADAMDEC1 expression, we tested whether ADAMDEC1 forms a positive feedback 
loop in GSCs with FGFR1 and ZEB1. Indeed, FGF2 treatment induced expression of 
ADAMDEC1 compared to EGF stimulation (Fig. 6A). We tested whether this effect on 
ADAMDEC1 expression was mediated by FGFR1, and found that FGFR1 knockdown 
reduced ADAMDEC1 expression, while targeted expression of FGFR1 increased 
ADAMDEC1 levels (Fig. 6B), and potentiated cell viability after ADAMDEC1 loss (Fig. S7B). 
ZEB1 knockdown also decreased ADAMDEC1 protein expression (Fig. 6C), while over-
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expression of ZEB1 increased ADAMDEC1 levels (Fig. 6D) and rescued its expression after 
knockdown of ZEB1 (Fig. 6E) or FGFR1 (Fig. 6F). While a recent study assessing ZEB1 
binding sites in the genome of GSCs found no evidence for ZEB1 binding to the 
ADAMDEC1 promoter (30), ZEB1 frequently exerts its transcriptional effects through 
repression of microRNAs such as miR-200c or miR-203 (31), which we have previously 
described in GSCs (7). Using miRWalk (32), we identified predicted binding sites for miR-
203 in the coding sequence of ADAMDEC1 (Fig. 6G), but not for miR-200c. We therefore 
over-expressed miR-203 and miR-200c in GBM cells, and found that only miR-203 
decreased expression of ADAMDEC1 (Fig. 6H), while both microRNAs repressed ZEB1, as 
described previously (31). Based on these studies, we conclude that ZEB1 can regulate 
ADAMDEC1 through repression of miR-203. 
Finally, we sought to identify how FGFR1 signals to ZEB1. A phospho-protein array 
revealed ERK1/2, STAT3, AKT and p38 as candidate targets in our GBM cells after FGF2 
stimulation (data not shown). Western blotting for phosphorylation of these candidate 
signaling molecules in control and FGFR1-knockdown cells demonstrated that only ERK1/2-
phosphorylation was attenuated after depletion of FGFR1 (Fig. 7A). This indicates the ERK 
signaling cascade as effector pathway for mediating stemness upon FGFR1 activation. To 
validate this, we used an ERK1/2 inhibitor (SCH772984, (33); Fig. 7B), and confirmed that 
this molecule could completely block ERK1/2 activation after treatment with FGF2 (Fig. 7C). 
Importantly, this inhibitor decreased expression of ZEB1 and ADAMDEC1 within 30 minutes 
of treatment (Fig. 7D), indicating that ERK1/2 may also directly regulate ADAMDEC1 
expression. 
Together, our data support the existence of a positive feedback loop that activates 
stemness in GBM (Fig. 7E). ADAMDEC1 is secreted by GSCs, and releases FGF2 from the 
ECM in the tumor microenvironment. FGF2 binds to FGFR1 on the surface of GSCs, where 
activation of this receptor leads to increased ERK1/2 signaling, resulting in expression of the 
downstream targets ADAMDEC1, ZEB1, SOX2 and OLIG2. ZEB1 mediates FGF2/FGFR1 
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effects on stemness, and regulates expression of ADAMDEC1, through miR-203, thereby 
completing the loop.  
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Discussion 
The mechanisms by which GSCs maintain their stemness across different niches in 
the tumor landscape, including hypoxic, vascular, invasive niches, is incompletely 
understood and a matter of intense investigation (14). Our study identifies a new feedback 
loop that enables GSCs to access FGF2 in the tumor microenvironment through secretion of 
the ADAMDEC1. ADAMDEC1 is a novel member of the ADAM family of metalloproteinases 
due to the absence of a transmembrane domain and altered catalytic domain, features 
shared by no other ADAM family member (20,34,35), that results in a unique secreted, 
soluble protease with distinct ligand specificity (20,21). Additionally, ADAMDEC1 was shown 
to modulate apical membrane extrusion of epithelial cells (36). Here, we demonstrate that 
ADAMDEC1 is highly expressed in glioma with enhanced expression correlating to 
increasing with tumor grade, and ADAMDEC1 expression correlated with patient survival. 
Further, we demonstrate that ADAMDEC1 was enriched in GSC populations and regulated 
cell proliferation, sphere formation and tumorigenesis. ADAMDEC1 was recently shown to 
mediate the cleavage and release of active EGF, an important GSC trophic factor (21), 
although in our data FGF2 had a stronger effect on GSC stemness than EGF alone. 
FGF2 binds to all four members of the FGF receptor family, with splice isoforms 
mediating binding affinity (37). FGF2/FGFR1 signaling promotes glioma growth and 
radioresistance (38,39) and higher FGFR1 expression is associated with poor outcome for 
these tumors (40). A recent study indicated a link between FGFR1 and ZEB1 in GBM (41), 
but definitive evidence for FGFR1 regulating stemness including limiting-dilution in vivo 
transplantation was lacking. This is presented in our study. By contrast, FGFR2 expression 
is reduced in GBM compared to low-grade glioma (42), and higher FGFR2 levels are 
associated with improved survival (43). Contrastingly, a recent study found that FGFR2 
signaling mediates GBM radioresistance (44). FGFR3 is the second-most differentially 
expressed gene between infiltrating and tumor-core GBM cells in a recent single-cell study 
(45), and FGFR3-TACC3 gene fusions have been identified as oncogenic drivers of GBM 
growth (46). 
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FGF2 activates FGFR1 on the GSC cell surface, which in turn induced expression of 
stem cell transcription factors. Crucially, FGFR1 was the only FGFR that we found to be 
functionally associated with tumor cell sphere formation in culture, a hallmark of stemness. 
The relevance of FGFR1 for GSCs is further supported by increased survival after loss of 
FGFR1, as well as increased tumorigenicity of FGFR1+ cells. We and others have shown 
that ZEB1 is a key regulator of stemness, invasion and chemoresistance in GBM (7,12,30), 
and consistently we find that ZEB1 mediates the stemness effects of FGF2/FGFR1 
signaling. Singh and colleagues have recently demonstrated that ZEB1, SOX2 and OLIG2 
form an autonomous transcriptional loop in GBM, and can regulate their expression 
reciprocally (26). Our data supports this, as the FGF2/FGFR1 complex activates expression 
of SOX2 and OLIG2 in our system as well, and ZEB1, SOX2, and OLIG2 are linked in 
hierarchical cluster analysis of TCGA data. It is tempting to speculate due to the apparent 
co-dependency of the transcription factors ZEB1, SOX2 and OLIG2 that interference with 
any one member of this circuit may disrupt stemness in GSCs. Our data indicate this may be 
the case, as loss of ZEB1 was sufficient to abrogate the effects of FGF2 stimulation and 
increased FGFR1 expression on GSCs. 
 We additionally found that ZEB1 regulates expression of ADAMDEC1, creating a 
feedback loop that would enable GSCs to thrive in the CNS, as FGF2 is highly prevalent 
across the brain. We find that in the TCGA dataset, approximately 30% of GBM patients are 
characterized by increased expression of FGF2, FGFRs, and ZEB1, and thus may benefit 
from therapeutic intervention aimed at disrupting this feedback loop. Importantly, we show 
that pharmacological intervention of FGF2 binding to its cognate receptors can block 
stemness in GSCs, indicating that this may be an exploitable fulcrum for future therapies. 
This may be particularly relevant for those patients, where cluster analysis shows higher 
expression of components of this feedback loop. Currently, clinical trials are underway for 
FGF receptor tyrosine kinase inhibitors (47). While these compounds are selective for 
FGFR1-3 over FGFR4, no compounds exist at present that are selective for FGFR1 over 
FGFR2-4. Furthermore, trials for FGFR inhibitors in glioma only recruit patients with 
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amplification or mutation of FGFR genes, which constitute only approximately 3-5% of all 
GBM patients (47). Our data indicate that a much larger fraction of patients could benefit 
from anti-FGFR therapies by targeting treatment-resistant GSCs, should such trials be 
successful. Taken as a whole, our data identify a novel GSC signaling axis: ADAMDEC1-
FGF2-FGFR1-ZEB1 and present a druggable, translational point of fragility. 
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Methods 
Primary human glioblastoma cells 
Human glioblastoma (hGBM) cells were cultured as described previously (7,12). Briefly, for 
GSC sphere culture, 5x104 cells/ml were plated in N2 medium (Thermo Fisher) 
supplemented with 2% bovine serum albumin (Fisher Scientific) containing 20 ng/ml 
recombinant human EGF (Peprotech). For some experiments, recombinant human FGF2 
(Peprotech) was added at concentrations ranging from 5 ng/ml to 80 ng/ml. For 
differentiation experiments, spheres were dissociated into single cells and plated in 
DMEM/F12 (Thermo Fisher) supplemented with 10% fetal bovine serum (FBS) or 25 ng/ml 
recombinant human BMP4 (Peprotech).  
Cell lines from the HGCC repository (28) were cultured in Neurobasal medium (Thermo 
Fisher) supplemented with B27 (Thermo Fisher) and 20ng/ml EGF and FGF2. Spheres were 
passaged when they reached an average diameter of 150 µm. 
In some experiments, previously established GBM xenografts obtained from Duke University 
and the University of Florida were used and maintained as previously described (48,49). 
Tissue was digested with papain (Worthington) as previously described (49) and dissociated 
cells allowed to recover overnight prior to use. Thereafter, dissociated cells were sorted 
based on CD133 expression using magnetic beads (Miltenyi). CD133‐positive CSCs were 
maintained in Neurobasal medium (Life Technologies) supplemented with 
penicillin/streptomycin (50 U/ml final concentration), L‐glutamine (2 mM), B27 (Life 
Technologies), sodium pyruvate (1 mM), EGF (20 ng/ml, R&D Systems) and FGF2 (20 
ng/ml, R&D Systems). CD133‐negative NSTCs were cultured in DMEM supplemented with 
10% FBS and penicillin/streptomycin (50 U/ml).  
 
Plasmids and lentiviral transduction 
Control and knockdown ZEB1, FGFR1, FGFR2 and FGFR3 plasmids were purchased from 
Dharmacon. Plasmids for expression of miR-203 and miR-200 were a gift from Thomas 
Brabletz (University of Erlangen, Germany). Control and knockdown ADAMDEC1 plasmids 
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were purchased from Sigma. Different clones for each shRNA plasmid were tested and the 
best knockdowns were selected to produce lentiviral particles. A plasmid for overexpression 
of FGFR1 was a gift from Dominic Esposito (Addgene plasmid #70367) and cloned into an 
expression vector (pHIV-IRES-mRFP) using the Gateway system (Invitrogen). Lentiviral 
particles were generated by co-transfecting HEK293T cells with second generation 
packaging plasmids (psPAX2 and pMD2.G) using Lipofectamine 3000 (Invitrogen). Medium 
containing lentiviral particles was collected 48 h and 72 h after transfection. Viral 
supernatants were combined and filtered with a 0.45 µm pore size filter, followed by 
ultracentrifugation at 185,000 rcf with a L8-70M Ultracentrifuge (Beckman). Pelleted viral 
particles were diluted in 200 µl of N2 medium. Concentrated viral particles were aliquoted 
and stored at -80ºC.  
For lentiviral transduction, 1x105 cells were pre-incubated for 1-2 h in N2 medium without 
antibiotics and 1g/l of polybrene (Santa Cruz) to increase transduction efficiency. 18h 
after transduction, medium was replaced with complete N2 medium and growth factors. 
 
FGF2 inhibitors 
The small molecule inhibitors of FGF2, NSC-47762, NSC-58057, NSC-65575 and NSC-
65576 (27) were obtained from the Developmental Therapeutics Program (DTP), division of 
Cancer Treatment and Diagnosis, NCI, NIH (USA). 
 
Sphere-forming frequency assays 
Limiting dilution analysis was carried out, following 14 days’ incubation, in a 96‐well format 
with 24 wells of each dilution; 1, 5, 10, and 20 cells/well. Cells were sorted using the BD 
FACS ARIA II Flow Cytometer. Limiting dilution plots and stem cell frequencies were 
calculated using ELDA analysis (http://bioinf.wehi.edu.au/software/elda/index.html) (29). 
Sphere-forming assays were performed as described (7), with the following modifications: 
100-200 single cells were seeded per well in 96 well plates, with 6 replicates per condition. 
Cells were cultured in 80µl of N2 medium supplemented with 20ng/ml of EGF and/or 
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30ng/ml of FGF2 as specified in the text. The number of spheres with a diameter greater 
than 70 µm was quantified on a GelCount analyzer (Oxford Optronix) 5 days after seeding. 
 
Clonogenicity assays 
For colony-forming cell assays, hGBM cells were cultured in N2 supplemented with 20ng/ml 
of EGF, 30ng/ml FGF2 and collagen (Stem Cell Technologies) at a ratio of 1:3 
(collagen/medium). Cells were supplemented with fresh growth factors twice/week. Colonies 
greater than 200µm of diameter were counted two weeks after plating on a GelCount 
analyzer. 
 
Flow cytometry and cell sorting 
Immunostaining and flow cytometry was performed as described (12). Data was acquired on 
a BD LSR Fortessa (BD Bioscience), using FACSDIVA software (BD Bioscience) and 
analyzed with a FlowJo ver. 8.8.7 (Tree Star, Inc). For cell sorting, stained single cell 
suspensions were purified on a BD FACSAria Fusion (BD Bioscience) and immediately used 
for downstream experiments. 
 
Protein isolation and Western blotting 
Protein isolation and quantification was performed as described (7,21). For Western blotting, 
5 to 20 µg of sample were mixed with equal volume of 2x Laemmli buffer (Bio-Rad) 
containing ß-mercaptoethanol, and denatured at 95°C for 5 min. Following separation on a 
mini-protean 4-15% Bis-Tris gel (Bio-Rad), proteins were transferred onto PVDF membranes 
using a Mini Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were blocked and 
probed for primary and secondary antibodies as described (7) (see Table S1 for antibody 
information), and visualized using Clarity Western ECL substrate (Bio-Rad) on a ChemiDoc 
MP imaging system (Biorad). Results were normalized to GAPDH or ACTNB as 
housekeeping genes.  
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Animal experiments 
Female SCID mice aged 4-6 weeks were used for orthotopic xenografts. Animal care and 
handling, and all procedures were performed according to NIH, FELASA and institutional 
guidelines and approved by the UK home office (PPL30/3331) and the Institutional Animal 
Care and Use Committee of the Cleveland Clinic Foundation (protocol 2012‐0752). 
Intracranial tumor transplants were performed as described previously (7,50). Depending on 
the experiment, 1,000 – 50,000 cells were stereotactically implanted in 5 µl of media devoid 
of growth factors/supplements. Mice were maintained under Isoflurane anesthesia during 
procedures. Mice were monitored daily for the development of neurological signs and body 
weight loss. Animals at endpoint were transcardially perfused using 2% paraformaldehyde 
and the brains removed for histology. 
 
Tissue preparation and immunofluorescence 
Post-fixed brains were cryoprotected, embedded and sectioned as described (51). Sections 
were prepared for immunofluorescence or immunohistochemistry staining, mounted and 
coverslipped using standard protocols. 
 
Bioinformatics 
TCGA, NCI, Gravendeel, Murat and Kamoun mRNA datasets were analyzed via the online 
tool GlioVis (http://gliovis.bioinfo.cnio.es/). Further analysis of survival correlations was 
performed using the Xena platform 
(https://www.biorxiv.org/content/early/2018/05/18/326470; https://xena.ucsc.edu/welcome-
to-ucsc-xena/). 
 
Hierarchical cluster analysis 
HGCC cell line expression data (28) was clustered using the hierarchical clustering module 
(52) from GenePattern (https://cloud.genepattern.org) (53) with Pearson correlation as 
distance measure, using row centering and normalization. Z-Score values from the 
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Glioblastoma Mutiforme (TCGA, Provisional) Tumor Samples with mRNA data (U133 
microarray only) (528 samples) data set was downloaded from cBioportal (54) and clustered 
with Pearson correlation as distance measure, using the same GenePattern module as 
before.  
Gene Set Enrichment Analysis was performed on our identified clusters using the GSEA 
module from GenePattern (55), this was done using the Glioblastoma Mutiforme (TCGA, 
Provisional) Tumor Samples with mRNA data (U133 microarray only) data set downloaded 
from UCSC Xena Platform website. Clusters were compared one versus the rest using the 
Verhaak Glioblastoma Proneural, Classical, Neural and Mesenchymal (4) gene sets from 
MsigDB (56). The results for the TCGA data set here are in whole or part based upon data 
generated by the TCGA Research Network: http://cancergenome.nih.gov/. 
 
Image acquisition 
Images were acquired using a Leica TCS-SP8-AOBS inverted confocal microscope (Leica 
Microsystems). 
 
Statistical analysis 
Statistical analyses were performed in GraphPad Prism version 7, using statistical tests as 
indicated in the text. In all analyses, p values <0.05 were deemed as significant. 
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Figure Legends 
Figure 1: ADAMDEC1 is associated with malignancy in GBM. (A) Expression of ADAM 
family metalloproteinases across different GBM datasets. Expression levels were normalized 
to normal brain tissue samples and are presented as fold change. ADAMDEC1 is highly 
expressed across all datasets. (B) Kaplan-Meier survival analysis of TCGA data, stratified 
for above-median (high) or below-median (low) gene expression shows a significantly poorer 
survival in ADAMDEC1 high tumors. (C) ADAMDEC1 mRNA expression levels are 
significantly increased in GBM compared to lower grade gliomas (TCGA). (D) 
Immunohistochemistry demonstrates ADAMDEC1 expression in GBM. (E) 
Immunofluorescence shows ADAMDEC1 is absent in tumor-associated microglia (left and 
center panels; scale bars 50 µm), but is expressed in human xenografted GBM cells (far 
right panel; GBM cells identified by human-specific Nestin; scale bar 10 µm). Nuclei are 
counterstained with DAPI. 
 
Figure 2: ADAMDEC1 is associated with GBM stemness and secreted by GSCs. (A) 
ADAMDEC1 protein is expressed in GSC, but not in NSTC culture paradigms. Likewise, 
GSCs secrete ADAMDEC1 into the medium. Depicted are Western blots from cell culture 
conditioned medium, with 10 µg protein lysate loaded per lane. (B) Knockdown of 
ADAMDEC1 using shRNA. Compared to non-targeting (NT) constructs, ADAMDEC1 
knockdown results in decreased SOX2 and increased GFAP expression. (C) Sphere-forming 
frequency is reduced after ADAMDEC1 knockdown (data from two independent 
experiments, one-way ANOVA). (D) ADAMDEC1 knockdown results in decreased cell 
proliferation in GSC cultures (n=6, non-linear regression). (E) Orthotopic implantation of 
ADAMDEC1 knockdown cells significantly increases survival of tumor-bearing animals 
compared to control cells (median survival NT=43 d, #4 and #5=100d; n=10 mice/group; log 
rank test). (F) Treatment of GSCs with recombinant ADAMDEC1 results in increased levels 
of FGF2, but not GRO alpha, in the culture supernatant in a concentration-dependent 
manner (n=3, two-way ANOVA with Dunnet post-test). (G) ELISA shows increased levels of 
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FGF2 in ADAMDEC1-treated GSC, but not in NSTC cultures (data from two independent 
experiments). (H) Western blot depicting FGFR phosphorylation after knockdown of 
ADAMDEC1, or after treatment with rADAMDEC1. 
 
Figure 3: FGF2 promotes sphere formation in GBM and is linked with FGFR1. (A) 
Spearman correlation of FGF2 with stem cell-associated transcription factors ZEB1, SOX2 
and OLIG2 using the Glioblastoma (TCGA, Provisional) Tumor Samples with mRNA data 
(U133 microarray only) dataset (n=528 samples) shows significant positive correlation for 
each factor. (B) Treatment of primary patient-derived GBM cells with recombinant FGF2 
increases ZEB1 expression in a dose-dependent manner. OLIG2 expression is also 
increased, whereas no change was found for SOX2. (C) FGF2 treatment results in 
increased sphere forming frequency of GSCs in a dose-dependent manner (hGBM L2 n=14, 
L0 n=10, one-way ANOVA). (D) Blocking FGF2 binding to FGFRs using a specific inhibitor 
(2-Naphthalenesulfonic acid, NSC 65575) reduces colony forming potential of GSCs dose-
dependently (n=5, one-way ANOVA). (E) Supervised hierarchical clustering of TCGA data 
(n=528) using FGF2, FGFR1-4, ZEB1, SOX2 and OLIG2 reveals three separate clusters. 
These clusters could be validated in the HGCC dataset (below) (see text for full description). 
(F) Kaplan-Meier survival analysis of TCGA GBM data, stratified for above-median (high) or 
below-median (low) gene expression shows a significantly poorer survival in FGFR1 high 
tumors, but increased survival of FGFR2 high tumors. FGFR3 expression has no effect on 
survival. Combined analysis of FGFR1 and ADAMDEC1 shows a very strong effect on 
survival. 
 
Figure 4: FGFR1 promotes stemness in GBM. (A) Western blotting shows expression of 
FGFR1-3, but not FGFR-4 in primary patient-derived GBM cell lines (hGBM L0, L1, L2). (B) 
Flow cytometry quantification of FGFR1-3 expression in patient-derived human GBM lines 
(n=3 independent experiments/sample). Note that FGFR1 is expressed in a small subset of 
each line. (C) Knockdown of FGFR1-3 using shRNA constructs shows specificity for each 
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receptor. Additional constructs are shown in Fig. S5. (D) Knockdown of FGFR1, but not 
FGFR2 or FGFR3, results in decreased sphere-forming frequency compared to control cells 
(hGBM L2 n=6, U3019 n=9, one-way ANOVA). (E) FGFR1 knockdown decreases 
expression of ZEB1, SOX2 and OLIG2 in GSCs. (F) Orthotopic implantation of FGFR1 
knockdown cells significantly increases survival of tumor-bearing animals (median survival 
shCo: 43d, shFGFR1#1: 54.5d, shFGFR1#2: 49d; log-rank test). (G) Limiting-dilution 
orthotopic implantation reveals FGFR1 knockdown reduces tumorigenic potential. Stem cell 
frequency was calculated using ELDA (Chi square test). (H) Expression of full-length FGFR1 
increases ZEB1 expression in control cells, and rescues ZEB1 expression in FGFR1 
knockdown cells. (I) Full-length FGFR1 expression increases sphere-forming frequency in 
control cells (black bars), and rescues sphere-forming frequency of FGFR1 knockdown cells 
to control levels (blue bars). Knockdown of ZEB1 negates the effect of FGFR1 expression 
(white bars) (n=9, two-way ANOVA). 
 
Figure 5: FGFR1 is endogenously associated with a stem cell population. (A) 
Expression of FGFR1, FGFR2, ZEB1, and SOX2 is affected by the culture paradigm. 
FGFR1, ZEB1 and SOX2 expression are higher in GSC conditions, whereas FGFR2 and 
FGFR3 increase upon differentiation (diff.). Schematic diagram reprinted with permission, 
Cleveland Clinic Center for Medical Art & Photography © 2019. All Rights Reserved. (B) 
Flow cytometry isolation of FGFR1+ cells. Histogram shows positive FGFR1 staining in GBM 
cells compared to isotype control. Additional plots are shown in Fig. S5. Western analysis 
using an independent FGFR1 antibody demonstrates higher FGFR1 expression in FGFR1+ 
cells post sort, as well as increased ZEB1, SOX2 and OLIG2 expression. (C) FGFR1+ cells 
show greater potential for colony formation in a collagen matrix. Cells were plated in limiting-
dilution colony forming assays immediately after sorting (2-way ANOVA). (D) Limiting 
dilution orthotopic xenografts reveal greater tumorigenicity of FGFR1+ cells. Stem cell 
frequency was calculated using ELDA (Chi square test). 
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Figure 6: FGFR1 regulates ADAMDEC1 through ZEB1. (A) Western analysis shows 
increased ADAMDEC1 expression after GSC treatment with FGF2. (B) ADAMDEC1 
expression is decreased after FGFR1 knockdown and increased after FGFR1 expression in 
GSCs. (C) ZEB1 knockdown results in decreased expression of ADAMDEC1. (D) ZEB1 
overexpression increases ADAMDEC1 levels. Targeted expression of ZEB1 rescues 
ADAMDEC1 after ZEB1 (E) or FGFR1 (F) knockdown. (G) Predicted miR-203 binding sites 
in the ADAMDEC1 CDS. (H) Expression of miR-203, but not miR-200c, results in loss of 
ADAMDEC1. 
 
Figure 7: FGFR1 induces ZEB1 and ADAMDEC1 through ERK1/2 signaling. (A) 
Treatment with FGF2 induces phosphorylation of ERK1/2, p38 and STAT3 in control cells, 
but only ERK1/2 phosphorylation is attenuated by FGFR1 knockdown. (B) ERK1/2 inhibitor 
SCH772984 blocks phosphorylation concentration-dependently. (C) SCH772984 attenuates 
ERK1/2 phosphorylation after FGF2 treatment. (D) ERK1/2 inhibition decreases expression 
of ZEB1 and ADAMDEC1. (E) Diagram depicting the ADAMDEC1-FGFR1-ZEB1 feedback 
loop. Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 
2019. All Rights Reserved. 
Research. 
on October 7, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2019; DOI: 10.1158/2159-8290.CD-18-1308 
TCGA NCI GRAV MURAT KAMOUN
adamdec1
adam9
adamts5
adam17
adamts9
adam12
adam10
adamts1
adamts3
adam28
adam19
adam15
adamts20
adam8
adamts2
adam20
adamts12
adam18
adamts7
adamts13
adam7
adam29
adamts6
adam2
adam30
adam22
adam23
adam11
adamts8
adam33
adam32
adam21
adamts4
adamts10
adamts14
adamts15
adamts16
adamts17
adamts18
adamts19
GBM
Normal
528
10
219
28
159
8
80
4
11
9
997
59
Total
Expression in GBM
<0.75 >1.25
A
0 2000 4000 6000
0
20
40
60
80
100
Time (Days)
P
er
ce
nt
 S
ur
vi
va
l
ADAMDEC1 high 
(n=130; median survival 385 d)
ADAMDEC1 low 
(n=130; median survival 737 d)
Log Rank test p<0.0001
B
C
D
E
Specimen 4001 H&E
ADAMDEC1
10 µm
human GBM cells   ADAMDEC1 DAPI
50 µm 
T3691 Xenograft
ADAMDEC1   Iba1   DAPI
50 µm 
ADAMDEC1   Iba1   DAPI
Figure 1
Research. 
on October 7, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2019; DOI: 10.1158/2159-8290.CD-18-1308 
EF
T4121 T3832 T387
GSCs + - + - + -
ADAMDEC1
ACTIN
cellular 
(non-secreted)
ADAMDEC1 media (secreted)
G
plate cells
(CSCs)
collect conditioned 
media
flow cytometry
bead array
48hrs treat with
 active rADAMDEC1
H
p-FGFR
FGFR1
(total)
ACTIN
T3832, GSC
T3832, NSCC
T387, GSC
T387, NSCC
FG
F2
 [p
g/
m
l]
FGF2 concentration in conditioned media
following rADAMDEC1 treatment
0’ 10
’
30
’
1 
h
4 
h
24
 h
A
ADAMDEC1
GFAP
SOX2
ACTIN
ADAMDEC1 shRNA
NT #1 #2 #3 #4 #5
Time (days)
0 20 40 60 80 100120
pe
rc
en
t s
ur
vi
va
l
0
20
40
60
80
100
NT (n=10; median survival 43d)
#4 (n=10; median survival 100d)
#5 (n=10; median survival 100d)
B C
D
0 2 4 6 8
0
5
10
15
fo
ld
 e
xp
an
si
on
 ra
te
T387 NT
#4
#5
0 2 4 6 8
0
5
10
15
T3832 NT
#4
#5
0.0
0.1
0.2
0.3
sp
he
re
 fo
rm
in
g 
fre
qu
en
cy
T4121
0.00
0.05
0.10
0.15
0.20
T3832
sp
he
re
 fo
rm
in
g 
fre
qu
en
cy
NT #4 #5 NT #4 #5
p<0.0001 p<0.0001
T4121 ADAMDEC1 shRNA
NT #1 #2 #3 #4 #5
CM 2
x 1x
1:1
0x
1:1
00
x
1:1
00
0x
me
dia
 al
on
e CM 2
x 1x
1:1
0x
1:1
00
x
1:1
00
0x
me
dia
 al
on
e
0
200
400
600
800
1000
1200
pr
ot
ei
n 
co
nc
en
tra
tio
n 
(p
g/
m
l)
T4121
FGF2 GRO alpha
n.s.
p<0.0001
p<0.0001 p<0.0001
Time post treatment
0
200
400
600
800
1000
1200
CM 2
x 1x
1:1
0x
1:1
00
x
1:1
00
0x
me
dia
 al
on
e
FGF2
hGBM L0
p<0.0001
rADAMDEC1 condtioned media (CM)
0
10
20
30
T4121
0
500
1000
1500
0’ 10
’
30
’
1 
h
4 
h
24
 h 0
’
10
’
30
’
1 
h
4 
h
24
 h 0’ 10
’
30
’
1 
h
4 
h
24
 h
0 2 4 6 8
0
2
4
6
8
10
days in vitro days in vitro days in vitro
NT
#4
#5
T4121
p<0.0001
T4121
p<0.001
T4121
rADAMDEC1 +-
pFGFR
Actin
Figure 2
Research. 
on October 7, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2019; DOI: 10.1158/2159-8290.CD-18-1308 
A hGBM L0 hGBM L1
ZEB1
FGF2 (ng/ml)
0 1 10 20 30
hGBM L0
C
EG
F 5 30 50
0
0.05
0.1
0.15
0.2
+FGF2 (ng/ml)
p=0.0095
hGBM L2
sp
he
re
 fo
rm
in
g 
fr
eq
ue
nc
y
0
0.2
0.4
0.6
EG
F 5 30 50
+FGF2 (ng/ml)
p=0.0199
hGBM L0
F
FGF2
FGFR1
FGFR2
FGFR3
FGFR4
SOX2
ZEB1
OLIG2
Cluster 1 Cluster 2 Cluster 3
row min row maxrow mean
TCGA z-score
B
E
2000
Pe
rc
en
t s
ru
vi
va
l
Time (days)
Overall survival of FGFR1
Overall survival of FGFR1 + ADAMDEC1
Pe
rc
en
t s
ru
vi
va
l
Overall survival of FGFR2
Pe
rc
en
t s
ru
vi
va
l
Overall survival of FGFR3
FGFR1 high 
(n=130; median survival 375 d)
FGFR1 low 
(n=130; median survival 771 d)
Log Rank Test p < 0.0001
Log Rank Test p < 0.0001
FGFR1 + ADAMDEC1 high 
(n=71; median survival 317 d)
FGFR1 + ADAMDEC1 low 
(n=71; median survival 1137 d)
FGFR2 high
(n=130; median survival 648 d)
FGFR2 low 
(n=130; median survival 448 d)
Log Rank Test p = 0.0006
FGFR3 high
(n=130; median survival 506 d)
FGFR3 low 
(n=130; median survival 535 d)
Log Rank Test p = 0.2049
0
20
40
60
80
100
4000 60000
0
20
40
60
80
100
2000
Time (days)
4000 60000
2000
Time (days)
0
20
40
60
80
100
4000 60000 2000
Time (days)
0
20
40
60
80
100
4000 60000
Pe
rc
en
t s
ru
vi
va
l
OLIG2
ZEB1
SOX2
GAPDH
D
0
20
40
60
# 
co
lo
ni
es
/w
el
l
hGBM L0
12.5 25
FGF2 inhibitor
[µM]
0
20
40
# 
co
lo
ni
es
/w
el
l
hGBM L1
p=0.0006
GAPDH
sp
he
re
 fo
rm
in
g 
fr
eq
ue
nc
y
TCGA correlation
Spearman r
95% CI
p value
sample number
FGF2 vs. ZEB1 FGF2 vs. SOX2 FGF2 vs. OLIG2
0.3085 0.25840.3739
0.2958 - 0.447 0.2268 - 0.3859 0.1745 - 0.3385
<0.0001
528
<0.0001
528
<0.0001
528
0 12.5 25
FGF2 inhibitor
[µM]
0
colony formation assay limiting dilution sphere formation
0.00
0.05
0.10
0.15
sp
he
re
 fo
rm
in
g 
fre
qu
en
cy
0.00
0.05
0.10
0.15
sp
he
re
 fo
rm
in
g 
fre
qu
en
cy
T387 T4121
12.5 25
FGF2 inhibitor
[µM]
0 12.5 25
FGF2 inhibitor
[µM]
050 50
p < 0.0001 p < 0.0001
p=0.0419
FGF2
FGFR1
FGFR3
FGFR2
ZEB1
FGFR4
U
3017
U
3042
U
3016
U
3013
U
3019
U
3046
U
3121
U
3034
U
3056
U
3005
U
3062
U
3031
U
3048
U
3002
U
3086
U
3009
U
3028
U
3047
U
3021
U
3024
U
3085
U
3065
U
3020
U
3027
U
3067
U
3037
U
3008
U
3123
U
3033
U
3060
U
3068
U
3035
U
3071
U
3029
U
3101
U
3073
U
3084
U
3117
U
3118
U
3053
U
3039
U
3078
U
3110
U
3051
U
3088
U
3082
U
3054
MES
PRO
CLA
NEU
HGCC z-scorerow min row maxrow mean
Cluster 1 Cluster 2 Cluster 3
subclass
0 2000 4000 6000
Time (Days)
0
20
40
60
80
100
Pe
rc
en
t s
ru
vi
va
l
Overall survival of FGFR4
FGFR4 high
(n=130; median survival 492 d)
FGFR4 low 
(n=130; median survival 532 d)
Log Rank Test p = 0.1819
subclass:
Figure 3
FGF2 (ng/ml)
0 030 30
Research. 
on October 7, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2019; DOI: 10.1158/2159-8290.CD-18-1308 
BFGFR1
FGFR3
GAPDH
sh
Co
sh
FG
FR
1
sh
FG
FR
2
sh
FG
FR
3
FGFR2
hGBM L2
0
0.05
0.1
0.15
0.2
0.25
sh
FG
FR
1
sh
FG
FR
2
sh
FG
FR
3
sh
C
o
sp
he
re
 fo
rm
in
g 
fr
eq
ue
nc
y
hGBM L2
Time (Days)
pe
rc
en
t s
ur
vi
va
l
shCo (n=7; median survival 43d)
shFGFR1 #1 (n=8; median survival 54.5d)
C
E
sh
FG
FR
1
sh
FG
FR
2
sh
FG
FR
3
sh
C
o
U3019
0
0
20
40
60
80
100
hGBM L2
0
0.02
0.04
0.06
0.08
0.1
p<0.001
H hGBM L0I
shCo shFGFR1 shZEB1
A
FG
FR
1
FG
FR
2
FG
FR
3
0
10
20
30
40
50
60 hGBM L2
FG
FR
1
FG
FR
2
FG
FR
3
0
10
20
30
40
hGBM L1
FG
FR
1
FG
FR
2
FG
FR
3
0
10
20
30
40
50
%
 to
ta
l c
el
ls
hGBM L0
%
 to
ta
l c
el
ls
%
 to
ta
l c
el
ls
FGFR1
FGFR2
FGFR3
FGFR4
GAPDH
GAPDH
po
s. 
co
.
hGBM L0 L1 L2
D
F
sh
Co
sh
FG
FR
1
L2
GAPDH
ZEB1
OLIG2
sh
Co
sh
FG
FR
1
L0hGBM
SOX2
U3019
sh
Co
sh
FG
FR
1
sh
FG
FR
2
sh
FG
FR
3
hGBM L0
ve
ct
or
+
FG
FR
1
FGFR1
GAPDH
ZEB1
sh
FG
FR
1
 
 
+
ve
ct
or
sh
FG
FR
1
 
 
+
FG
FR
1
0
5
10
15
20
25
FG
FR
1
FG
FR
2
FG
FR
3
U3019
%
 to
ta
l c
el
ls
3030 40 50 60
shFGFR1 #2 (n=7; median survival 49d)
p<0.0001
0
0.1
0.2
0.3
0.4
0
0.1
0.2
0.3
0.4
sp
he
re
 fo
rm
in
g 
fr
eq
ue
nc
y
sp
he
re
 fo
rm
in
g 
fr
eq
ue
nc
y
ve
ct
or
+
FG
FR
1
ve
ct
or
+
FG
FR
1
ve
ct
or
+
FG
FR
1
ve
ct
or
+
FG
FR
1
0
0.1
0.2
0.3
sp
he
re
 fo
rm
in
g 
fr
eq
ue
nc
y
0
0.1
0.2
0.3
sp
he
re
 fo
rm
in
g 
fr
eq
ue
nc
y
ve
ct
or
+
FG
FR
1
ve
ct
or
+
FG
FR
1
ve
ct
or
+
FG
FR
1
ve
ct
or
+
FG
FR
1
hGBM L1
p<0.01
n.s.
p<0.01
p<0.05
p<0.001 p<0.001
p<0.01
n.s.
sp
he
re
 fo
rm
in
g 
fr
eq
ue
nc
y
hGBM L1
sh
ZE
B1
 
 
+
ve
ct
or
sh
ZE
B1
 
 
+
FG
FR
1
SOX2
OLIG2
ve
ct
or
+
FG
FR
1
FGFR1
GAPDH
ZEB1
sh
FG
FR
1
 
 
+
ve
ct
or
sh
FG
FR
1
 
 
+
FG
FR
1
sh
ZE
B1
 
 
+
ve
ct
or
sh
ZE
B1
 
 
+
FG
FR
1
SOX2
OLIG2
p<0.01p<0.001
50,000 10,000 1,000
shCo
shFGFR1
# cells implanted
# animals with tumor
4/4 5/6 5/6
3/4 4/6 2/6
p=0.00124
stem cell 
frequency
1 / 2,485
1 / 14,611
hGBM L0G
Figure 4
Research. 
on October 7, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2019; DOI: 10.1158/2159-8290.CD-18-1308 
FGFR1
FGFR2
SOX2
GAPDH
G
SC
di
ff.
ZEB1
FGFR3
A
FGFR1
SOX2
GAPDH
ZEB1
B
C
D
FGFR1
+ -
50,000 10,000 1,000
FGFR1+
FGFR1-
# cells implanted
# animals with tumor
3/3 5/6 2/6
3/4 2/6 1/6
p=0.0043
stem cell 
frequency
1 / 4,479
1 / 26,227
hGBM L0
hGBM L2
hGBM L0
U3019
G
SC
di
ff.
0-103 103 104 105
0
200
400
600
C
ou
nt
FGFR1
Isotype control
anti-FGFR1
FGFR1+FGFR1-
OLIG2
OLIG2
Co
lo
ni
es
 p
er
 w
el
l
 hGBM L0
FGFR1+
FGFR1-
Co
lo
ni
es
 p
er
 w
el
l
hGBM L1
FGFR1+
FGFR1-
plated cells x1000 plated cells x1000
2.5 1.25 0.75
0
20
40
60
0
20
40
60
2.5 1.25 0.75
p<0.0001 p=0.0002
Figure 5
Research. 
on October 7, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2019; DOI: 10.1158/2159-8290.CD-18-1308 
B CA
D
hGBM L0
ADAMDEC1
GAPDH
hGBM L0
ADAMDEC1
GAPDH
sh
C
o
sh
FG
FR
1
ve
ct
or
+ 
FG
FR
1
hGBM L1
sh
C
o
sh
FG
FR
1
hGBM L0
ADAMDEC1
GAPDH
ADAMDEC1
GAPDH
hGBM L0 hGBM L1
sh
C
o
sh
ZE
B1
sh
C
o
sh
ZE
B1
hGBM L1 hGBM L1
ve
ct
or
+ 
FG
FR
1
hGBM L0 hGBM L1
sh
Co
+Z
EB
1
sh
Co
+Z
EB
1
sh
Co
+v
ec
tor
sh
Co
+v
ec
tor
GAPDH
ZEB1
ADAMDEC1
hGBM L0
sh
ZE
B1
+Z
EB
1
sh
ZE
B1
+v
ec
tor
hGBM L1
sh
ZE
B1
+Z
EB
1
sh
ZE
B1
+v
ec
tor
hGBM L0
sh
FG
FR
1
+Z
EB
1
sh
FG
FR
1
+v
ec
tor
hGBM L1
GAPDH
ZEB1
ADAMDEC1
sh
FG
FR
1
+Z
EB
1
sh
FG
FR
1
+v
ec
tor
GAPDH
ZEB1
ADAMDEC1
E F
hsa-miR-203a-5p
ADAMDEC1 ...tgacaacaccagtgtgtgggaaccacc...
UUGACAACUUGACAAUUCUUGGUGA..
1473 1499
5’3’
G
...tagtttgtcctaaaaaacttcacattttaca...
GAUCACCAGGAUUUGUAAAGUG
350 381
5’3’hsa-miR-203a-3p
ADAMDEC1
hGBM L1
GAPDH
ZEB1
ADAMDEC1
ve
cto
r
mi
R-
20
0c
mi
R-
20
3
H
Figure 6
FGF2 (ng/ml)
0 030 30
Research. 
on October 7, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2019; DOI: 10.1158/2159-8290.CD-18-1308 
hGBM L1
pERK1/2
ERK1/2
GAPDH
shCo shFGFR1
+FGF20’ 10’ 30’ 60’ 0’ 10’ 30’ 60’
p-p38
p38
hGBM L0
pERK1/2
ERK1/2
shCo shFGFR1
pAKT
pSTAT3
STAT3
GAPDH
A hGBM L0
pERK1/2
ERK1/2
GAPDH
0 10 20 40
ERK1/2 inhibitor [nM]
hGBM L0
FGF2 
+ ERK1/2 
inhibitor
0’ 10’ 30’
FGF2 
+ DMSO
pERK1/2
ERK1/2
GAPDH
0’ 10’ 30’
B C
hGBM L0
pERK1/2
GAPDH
ZEB1
ADAMDEC1
ER
K
1/
2 
in
hi
bi
to
r
D
M
SO
hGBM L1
GAPDH
ZEB1
ADAMDEC1
ER
K
1/
2 
in
hi
bi
to
r
D
M
SO
D
E
+FGF20’ 10’ 30’ 60’ 0’ 10’ 30’ 60’
Figure 7
Research. 
on October 7, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2019; DOI: 10.1158/2159-8290.CD-18-1308 
 Published OnlineFirst August 21, 2019.Cancer Discov 
  
Ana Jimenez-Pascual, James S Hale, Anja Kordowski, et al. 
  
cancer stem cells
ADAMDEC1 maintains a growth factor signaling loop in
  
Updated version
  
 10.1158/2159-8290.CD-18-1308doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://cancerdiscovery.aacrjournals.org/content/suppl/2019/08/17/2159-8290.CD-18-1308.DC1
Access the most recent supplemental material at:
  
Manuscript
Author
been edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerdiscovery.aacrjournals.org/content/early/2019/08/17/2159-8290.CD-18-1308
To request permission to re-use all or part of this article, use this link
Research. 
on October 7, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2019; DOI: 10.1158/2159-8290.CD-18-1308 
